ライフサイエンスコーパス: international normalized ratio

1 3 patients were on warfarin with therapeutic international normalized ratio.

2 etransplant cerebral edema and postoperative international normalized ratio.

3 atients underwent ablation under therapeutic international normalized ratio.

4 farin and warfarin can be monitored with the international normalized ratio.

5 sEPCR levels mirrored changes in values for international normalized ratios.

6 ped at creatinine 0.7-2.5, bilirubin 0.3-27, international normalized ratio 0.1-2.6, and sodium 120-1

7 x (creatinine(-0.836) ) x (urea(-0.229) ) x (international normalized ratio(-0.113) ) x (age(-0.129)

8 x (creatinine(-0.836) ) x (urea(-0.229) ) x (international normalized ratio(-0.113) ) x (age(-0.129))

9 to compare the efficacy of warfarin (target international normalized ratio 1.5 to 2.5 IU) plus aspir

10 tinine (0.8 and 3.0 mg/dL, respectively) and international normalized ratio (1 and 3, respectively).

11 lt using cutoff values of 2.2 or greater for international normalized ratio (1 point) and less than 1

12 53.71 IU/L; P = 0.04), and prothrombin time-international normalized ratio (1.16 + 0.36 vs 1.28 + 0.

13 Bilirubin (1.8 vs 2.2 mg/dL; P = .032) and international normalized ratio (1.4 vs 1.5; P = .022) in

14 cipients, postoperative days 7 and 14 median international normalized ratio (1.5 and 1.2, respectivel

15 r compared with RL recipients (7 and 14 days international normalized ratio [1.2, P < 0.001; 1.1, P =

16 , 0.378 vs 0.939 [95% CI, 0.91-0.97]; log(e) international normalized ratio, 1.120 vs 1.658 [95% CI,

17 s demonstrated by normal coagulation values (international normalized ratio, 1.19; reference value, 0

18 y with either adjusted-dose warfarin (target international normalized ratio 2 to 3) or fixed-dose xim

19 ns for high-risk patients (warfarin therapy, international normalized ratio 2.0 to 3.0) and low-risk

20 ned warfarin, the time in therapeutic range (international normalized ratio 2.0 to 3.0) was 62% and 6

21 as well-controlled, adjusted-dose warfarin (international normalized ratio 2.0 to 3.0).

22 676 patients with ALF or acute liver injury (international normalized ratio 2.0 without hepatic encep

23 ratory evidence of hypocoagulability (median international normalized ratio = 2.9 and platelet count

24 evice (n = 463) or warfarin (n = 244; target international normalized ratio, 2-3).

25 errupted vitamin K antagonist phenprocoumon (international normalized ratio, 2-3).

26 e of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 pa

27 e daily) with dose-adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients

28 racranial artery to receive warfarin (target international normalized ratio, 2.0 to 3.0) or aspirin (

29 he vitamin K antagonist (VKA) phenprocoumon (international normalized ratio, 2.0 to 3.0).

30 Warfarin anticoagulation (target international normalized ratio, 2.0 to 3.0); dabigatran,

31 function) versus dose-adjusted VKAs (target international normalized ratio, 2.0 to 3.0, or 3.1 to 4.

32 r at least 6 months on oral anticoagulation (international normalized ratio, 2.0-3.0).

33 e morning after surgery, or warfarin (target international normalized ratio, 2.5 [range, 1.8 to 3.0])

34 risk factors randomized to warfarin (target international normalized ratio=2.0-3.0) or rivaroxaban (

35 arallel controls (percentage of out-of-range international normalized ratios 31% versus 42% at 1 mont

36 Among patients with abnormal international normalized ratios, 33% received fresh-froz

37 usions were all independent risk factors for international normalized ratio abnormalities (all p < .0

38 Most international normalized ratio abnormalities were minor

39 lation tests including prothrombin time, and international normalized ratio, activated partial thromb

40 lanine transaminase, aspartate transaminase, international normalized ratio, acute kidney injury, sep

41 k aspartate transaminase, day 5 bilirubin or international normalized ratio after transplant.

42 se, stroke history, prior bleeding, unstable international normalized ratio, age >65, drug or alcohol

43 nction, stroke, prior major bleeding, labile international normalized ratios, age 65 years or older,

44 l Organ Failure Assessment score, and higher international normalized ratio (all p</=0.001).

45 easure of synthetic liver function, based on international normalized ratio and albumin and bilirubin

46 The median (interquartile range) for international normalized ratio and bilirubin were highes

47 s of bleeding and laboratory measurements of international normalized ratio and factor levels.

48 MELD assigns lower weight to creatinine and international normalized ratio and higher weight to bili

49 quiring regular laboratory monitoring of the international normalized ratio and intermittent adjustme

50 The results showed that height, target international normalized ratio and VKORC1 and CYP2C9 gen

51 F is a continuous score, based on bilirubin, international normalized ratio, and alanine aminotransfe

52 r liver function, anticonvulsant use, labile international normalized ratio, and antihypertensive use

53 indirect bilirubin, aspartate transaminase, international normalized ratio, and creatinine.

54 ctioned, and serum transaminases, bilirubin, international normalized ratio, and lactate levels corre

55 seline levels of bilirubin, prothrombin time/international normalized ratio, and Model for End-Stage

56 ic biosynthetic capacity, such as albumin or international normalized ratio, and positively with non-

57 Creatinine, bilirubin, international normalized ratio, and sodium levels.

58 the 4 variables (ie, bilirubin, creatinine, international normalized ratio, and sodium) had a modest

59 antly lower blood ammonia, prothrombin time, international normalized ratio, and TGF-beta1 levels whe

60 onal status, serum albumin, serum bilirubin, international normalized ratio, and the presence of asci

61 with higher creatinine and bilirubin levels, international normalized ratio, and viral load.

62 logy, HE grade, use of IMV and vasopressors, international normalized ratio, and year), although pers

63 tivated partial thromboplastin time <= 50 s, international normalized ratio antithrombin III, fibrino

64 In this study, we validated the admission international normalized ratio as an independent risk fa

65 Only recipient's age and elevated international normalized ratio at LT were associated wit

66 tients had significantly lower bilirubin and international normalized ratio at waitlisting, and less

67 ary outcomes were percentage of out-of-range international normalized ratios at 1 and 3 months and pe

68 erior to PG-1 for percentage of out-of-range international normalized ratios at 1 month and 3 months

69 At the index event, the international normalized ratio averaged 1.67 +/- 0.53, a

70 utcomes after trauma and compared two common international normalized ratio-based definitions for acu

71 e (for an individual patient) to maintain an international normalized ratio between 2 and 3 was 15.6

72 ntly, warfarin was continued to maintain the international normalized ratio between 2 and 3.5 (group

73 whom were receiving acenocoumarol and had an international normalized ratio between 2.0 and 3.0 durin

74 S-TIPS prognostic index (PI) score (based on international normalized ratio, bilirubin, and age) was

75 Liver-related blood parameters (international normalized ratio, bilirubin, aspartate ami

76 s reproduces the empirical equations for the International Normalized Ratio calibration (INR), as wel

77 Patients with poor international normalized ratio control (i.e., time in th

78 0 mg (twice daily) was cost-effective unless international normalized ratio control was excellent (ti

79 he risk of hemorrhage was high or quality of international normalized ratio control was poor (time in

80 ctive in moderate-risk AF populations unless international normalized ratio control was poor.

81 of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was

82 centers' and patients' predicted quality of international normalized ratio control.

83 mostatic efficacy from start of infusion and international normalized ratio correction (</=1.3) at 0.

84 Commonly utilized thresholds for international normalized ratio correction are not suppor

85 End-Stage Liver Disease and age, bilirubin, international normalized ratio, creatinine scores), comp

86 d partial prothrombin time, prothrombin time international normalized ratio, D-dimer, tissue plasmino

87 , Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Dru

88 , Bleeding history or predisposition, Labile international normalized ratio, Elderly [>65 years], Dru

89 , bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol c

90 , bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol c

91 , bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol c

92 , bleeding history or predisposition, Labile international normalized ratio, elderly, drugs/alcohol c

93 oke, bleeding predisposition/history, labile international normalized ratio, elderly, drugs/alcohol)

94 , Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol).

95 eding history or predisposition, labile INR [international normalized ratio], elderly, drugs/alcohol

96 International normalized ratio exhibited a positive adju

97 y an MTP goal directed by TEG or by CCA (ie, international normalized ratio, fibrinogen, platelet cou

98 concentrations of bilirubin and creatinine, international normalized ratio for prothrombin time (INR

99 The preprocedure mean international normalized ratio for prothrombin time was

100 to oral anticoagulation (as assessed by the international normalized ratio for prothrombin time).

101 irubin and creatinine concentrations and the international normalized ratio for the prothrombin time.

102 sodium levels] and MELD-XI [does not include international normalized ratio]) for endpoint events, de

103 lasty and receiving warfarin prophylaxis, an international normalized ratio goal of 1.8 compared with

104 age older than 65 years, a prothrombin time international normalized ratio greater than 1.1, alpha-f

105 hy affected 50% of subjects if defined as an international normalized ratio greater than 1.2 and 21%

106 normalized ratio greater than 1.5 but not an international normalized ratio greater than 1.2 identifi

107 Acute traumatic coagulopathy defined as an international normalized ratio greater than 1.2 was not

108 r hemoglobin less than 8 gm/dL (p = 0.0006), international normalized ratio greater than 1.4 (p < 0.0

109 at least one organ system dysfunction and an international normalized ratio greater than 1.4 at basel

110 ing acute traumatic coagulopathy by using an international normalized ratio greater than 1.5 but not

111 e traumatic coagulopathy to patients with an international normalized ratio greater than 1.5 may yiel

112 , acute traumatic coagulopathy defined as an international normalized ratio greater than 1.5 was sign

113 r than 1.2 and 21% of subjects if defined by international normalized ratio greater than 1.5.

114 ional normalized ratio values (defined as an international normalized ratio > 1.5).

115 iciency (total bilirubin level > 10 mg/dL or international normalized ratio > 2) occurred in 6 patien

116 included adult patients on warfarin with an international normalized ratio >/=1.5 who received froze

117 serum creatinine level >3 mg/dL or oliguria; international normalized ratio >1.5 or transaminases >5

118 sociation with TIC as defined by laboratory (international normalized ratio >1.5) or clinical (transf

119 rauma-induced coagulopathy [(TIC), admission international normalized ratio >1.5].

120 y postoperative day 7 bilirubin >10 mg/dL or international normalized ratio >1.6), and graft failure.

121 re at a higher risk for overanticoagulation (international normalized ratio >4; P = 0.052), compared

122 There were fewer percentage international normalized ratios >/=4 and </=1.5 and seri

123 the DCD120'-group had a significantly higher international normalized ratio (>5) compared to the rest

124 elet count < 150x10(3)/mm(3)), coagulopathy (International Normalized Ratio>2.0), and renal insuffici

125 e of continuous renal replacement therapy or international normalized ratio had no effect on clotting

126 1; test for trend across 4 categories of the international normalized ratio), history of coronary art

127 se (HR, 1.35; 95% CI, 1.04-1.75), and labile international normalized ratio (HR, 1.33; 95% CI, 1.04-1

128 .7% vs. 2.5%; p = NS) despite increasing the international normalized ratio in a dose-related fashion

129 , alcoholic etiology, creatinine levels, and international normalized ratio in the overall cohort, an

130 nit mortality (p < .0001), particularly when international normalized ratio increased after intensive

131 0 days of warfarin, age > or = 80 years, and international normalized ratio (INR) > or = 4.0 were ass

132 P < 0.01), platelet <150 U/L (P < 0.01), and International Normalized Ratio (INR) >1.2 (P < 0.01).

133 Among warfarin-treated patients with international normalized ratio (INR) >5, we sought to de

134 merican guidelines accept IV tPA use with an international normalized ratio (INR) </= 1.7.

135 e recovery was reflected by normalization of International normalized ratio (INR) (80% of patients),

136 , 95% confidence interval [CI] = 1.35-3.21), international normalized ratio (INR) (P < 0.001, HR = 9.

137 ial fibrillation, it is unclear how baseline international normalized ratio (INR) affects the dosing

138 regimens is consistent across a range of the international normalized ratio (INR) among subjects admi

139 Before plasma transfusion, the median international normalized ratio (INR) and activated parti

140 We explored the relation between admission international normalized ratio (INR) and acute infarct v

141 uency of hematoma enlargement in relation to international normalized ratio (INR) and BP.

142 International normalized ratio (INR) and plasma warfarin

143 Data on international normalized ratio (INR) and platelet counts

144 Prothrombin time (PT) and the associated international normalized ratio (INR) are routinely teste

145 atment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0

146 rch has compared the measures of summarizing international normalized ratio (INR) control over time.

147 the therapeutic range of 2.0 to 3.0 for the international normalized ratio (INR) during the first 12

148 orrelates directly to duration and degree of international normalized ratio (INR) elevation above the

149 ts of serum bilirubin and creatinine levels, International Normalized Ratio (INR) for prothrombin tim

150 defined as platelets lower than 150 x 109/L, international normalized ratio (INR) greater than 1.4, o

151 s the risk of hemorrhage, particularly at an international normalized ratio (INR) greater than 4.0.

152 Current international normalized ratio (INR) guidelines are base

153 At 1 month international normalized ratio (INR) increased after RYG

154 arfarin on the baseline corrected AUC of the International Normalized Ratio (INR) increased by 2.8 ti

155 An elevated international normalized ratio (INR) increases the risk

156 substantial treatment by baseline laboratory international normalized ratio (INR) interaction effect

157 us tPA to warfarin-treated patients if their international normalized ratio (INR) is 1.7 or lower, th

158 but effective management is complex, and the international normalized ratio (INR) is often outside th

159 However, the optimal international normalized ratio (INR) levels during RFA h

160 egistry-Get With the Guidelines by admission international normalized ratio (INR) levels: subtherapeu

161 e (AST), alanine aminotransferase (ALT), and international normalized ratio (INR) measurements on adm

162 yridamole 75 mg daily (n = 26) with a target international normalized ratio (INR) of 2 to 3 from June

163 < or = 5 mg and > 5 mg necessary to keep an international normalized ratio (INR) of 2.5 to 3.5, and

164 days 1 through 11 of therapy and to a target international normalized ratio (INR) of either 1.8 or 2.

165 cument the increased risk for stroke when an international normalized ratio (INR) of less than 2.0 is

166 In the patients for whom the international normalized ratio (INR) of prothrombin time

167 sion support to optimize time in therapeutic International Normalized Ratio (INR) range.

168 For patients on warfarin therapy, an international normalized ratio (INR) recall interval not

169 warfarin daily dosage needed to reach target international normalized ratio (INR) represented the mai

170 Analysis using international normalized ratio (INR) suggested a dose-re

171 Frequent prothrombin time (PT) and international normalized ratio (INR) testing is critical

172 g warfarin dose and the number of predefined international normalized ratio (INR) thresholds for each

173 An acute increase in international normalized ratio (INR) to >3.0 in patients

174 5th, 75th percentiles) time from most recent international normalized ratio (INR) to ICH was 13 days

175 We used the international normalized ratio (INR) to measure the inte

176 The optimal international normalized ratio (INR) to prevent venous t

177 nts with CF-LVADs have suggested that target international normalized ratio (INR) values <2.5 (range,

178 tients treated with warfarin with a range of International Normalized Ratio (INR) values as well-char

179 However, these variants also affect early international normalized ratio (INR) values during warfa

180 nticoagulation, with the full effect seen at international normalized ratio (INR) values of 2.0 or gr

181 sed on genetic variables, clinical data, and international normalized ratio (INR) values.

182 Percent time in therapeutic range (TTR) and international normalized ratio (INR) variability both me

183 percent time in therapeutic range (TTR) and international normalized ratio (INR) variability predict

184 The international normalized ratio (INR) was absent in 3% of

185 outcome was the percentage of time that the international normalized ratio (INR) was in the therapeu

186 Prothrombin time international normalized ratio (INR) was measured routin

187 hen compared with holding warfarin until the international normalized ratio (INR) was normal (n = 258

188 itamin K antagonist was recommended, and the international normalized ratio (INR) was not to be measu

189 s of interest: age <1 year, total bilirubin, international normalized ratio (INR), albumin, growth fa

190 e of hepatotoxicity (ALT > 1,000 IU/L), peak international normalized ratio (INR), and adverse drug r

191 oplastin time (APTT), prothrombin time (PT), international normalized ratio (INR), and concentration

192 (AST), day-1 lactate, day-3 bilirubin, day-3 international normalized ratio (INR), and day-7 AST were

193 ctivated partial thromboplastin time (APTT), international normalized ratio (INR), and other measures

194 donor age (DnAge), serum creatinine (Creat), International Normalized Ratio (INR), and serum albumin

195 tracranial hemorrhage with regard to age and international normalized ratio (INR), controlling for co

196 on control with warfarin, as assessed by the international normalized ratio (INR), is challenging.

197 ctivated partial thromboplastin time (aPTT), international normalized ratio (INR), platelet count and

198 injury versus alanine transaminase (ALT) and International Normalized Ratio (INR).

199 in time monitoring should be reported as the International Normalized Ratio (INR).

200 bilirubin and prothrombin time expressed as International Normalized Ratio (INR).

201 with LT or death: age, etiology; coma grade; international normalized ratio (INR); serum pH; body mas

202 unger age (OR, 0.92; p = 0.004), lower index international normalized ratio (INR; 0.31; p = 0.03), an

203 ndrome: warfarin-associated supratherapeutic international normalized ratio (INR; median, 6.5) at ons

204 rcentage of time in the target range for the international normalized ratio (INR; target range, 2.0 t

205 (7.6%) were receiving therapeutic warfarin (international normalized ratio [INR] >/=2) and 8290 (8.8

206 aracterized by sudden onset of coagulopathy (international normalized ratio [INR] >= 1.5) and encepha

207 l coagulation assessment than routine tests (international normalized ratio [INR] and platelet [PLT]

208 l coagulation assessment than routine tests (international normalized ratio [INR] and platelet count)

209 alyzed altered prothrombin time (measured as international normalized ratio [INR]) after initiation o

210 s, response to therapy (as determined by the international normalized ratio [INR]), and bleeding even

211 A total of 676 patients with ALF (international normalized ratio [INR], >=1.5) or severe a

212 female), 3087 (9.4%) had used a VKA (median international normalized ratio [INR], 1.5 [IQR, 1.2-1.9]

213 A total of 676 patients with ALF (international normalized ratio [INR], 1.5) or severe acu

214 tween MELD-GRAIL-Na (re-estimated bilirubin, international normalized ratio [INR], sodium, and GRAIL)

215 Recommended therapeutic international normalized ratios (INRs) for oral anticoag

216 eparin, warfarin-associated supratherapeutic international normalized ratios (INRs), and evidence of

217 ted with vitamin K antagonists have unstable International Normalized Ratios (INRs), increasing the r

218 with AF had thromboembolic events at higher international normalized ratios (INRs).

219 in patients on warfarin therapy with similar international normalized ratios (INRs).

220 International normalized ratios less than 2.0 were not a

221 ith patients who often failed to meet target international normalized ratio level (HR: 3.53, 95% CI:

222 rin who consistently achieved minimum target international normalized ratio levels or those on acetyl

223 er, hypertriglyceridemic events and abnormal international normalized ratio levels were more common a

224 nd alanine aminotransferase, and prothrombin international normalized ratio; LR, 0.09; 95% CI, 0.03-0

225 After excluding 250 patients with international normalized ratio < 1.3 and/or missing data

226 ns (P = 0.012), coagulation status on POD 7 (international normalized ratio < 1.4; P = 0.027), and pr

227 ulation with NOACs versus those on warfarin (international normalized ratio <1.7) or not on anticoagu

228 ne triglyceride level <= 154 mg/dL, baseline international normalized ratio <= 1, baseline aspartate

229 idence interval, 1.51-6.51; P=0.002) and the international normalized ratio measured prior LT (OR=4.9

230 preoperative pulmonary testing and a higher international normalized ratio measured prior LT were as

231 ve class) to 100% (coronary risk assessment; international normalized ratio measured).

232 ass rates included coronary risk assessment, international normalized ratio measured, HbA1c measureme

233 3.4 [5.0] vs -7.8 [6.9]; P = .02), and worst international normalized ratio (median [interquartile ra

234 model for end-stage liver disease excluding international normalized ratio (MELD-XI score), as well

235 Model for End-Stage Liver Disease Excluding international normalized ratio (MELD-XI) score at the ti

236 venience as their dosages are independent of international normalized ratio monitoring.

237 perative temperature less than 95 degrees F, international normalized ratio more than 1.5, or a pH le

238 t cerebral edema and a higher posttransplant international normalized ratio (odds ratios and 95% conf

239 luded a prothrombin time of 15.4 seconds, an international normalized ratio of 1.2, and a partial thr

240 f warfarin (at a dose adjusted to produce an international normalized ratio of 1.4 to 2.8) and that o

241 rction patients, warfarin therapy (at a mean international normalized ratio of 1.8) combined with low

242 The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 o

243 bo-controlled trial of warfarin targeting an international normalized ratio of 2.0 to 3.0 in patients

244 to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin

245 linical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double

246 udies revealed a normal white-cell count, an international normalized ratio of more than 11, a prothr

247 mg/dL; female, 0.58 [0.64] mg/dL; P < .001; international normalized ratio of prothrombin rate: male

248 to calculate the MELD score were available (international normalized ratio of prothrombin time, tota

249 rovides maximal protection against stroke at international normalized ratios of 2.0 to 3.0.

250 Elevated international normalized ratio on hospital admission is

251 .85; 95% confidence interval, 0.79-0.92) and international normalized ratio (OR, 1.45; 95% confidence

252 rial fibrillation (OR: 5.19), subtherapeutic international normalized ratio (OR: 7.37), increased cus

253 antithrombin levels (p = 0.02), but not with international normalized ratio (p = 0.99) or activated p

254 artate aminotransferase and prothrombin time-international normalized ratio; postoperative morbidity

255 The international normalized ratio profile correlated poorly

256 ement, variability in prothrombin time-based international normalized ratio (PT-INR) is caused, in pa

257 erative serum bilirubin and prothrombin time-international normalized ratio (PT-INR) levels were also

258 ity (r=0.97), prothrombin time (r=0.77), and international normalized ratio (r=0.72) but less so with

259 on maintaining adequate time in therapeutic International Normalized Ratio range (TTR).

260 iated with the time spent above or below the international normalized ratio range.

261 Times in extreme international normalized ratio ranges of <1.5 and >4.0 w

262 Rapid international normalized ratio reduction was achieved in

263 in treatment is maintenance of a therapeutic international normalized ratio, regardless of the age of

264 Median international normalized ratio reversal was 11.8 hours w

265 Secondary outcomes included time to international normalized ratio reversal, hospital length

266 model for end-stage liver disease excluding international normalized ratio score) were assessed prei

267 ed Kingdom End-Stage Liver Disease) included international normalized ratio, serum creatinine, biliru

268 rained, baseline hemoglobin, platelet count, international normalized ratio, serum sodium, creatinine

269 The international normalized ratio should be tightly control

270 itoring, the difficulties in maintaining the international normalized ratio target (variable between

271 frozen plasma required to reach an arbitrary international normalized ratio target, limitations of th

272 ring devices, patients can conduct their own international normalized ratio testing and dose adjustme

273 International normalized ratio testing was not required

274 may yield greater returns than using a lower international normalized ratio threshold.

275 in time in critically ill patients using the international normalized ratio to standardize data and e

276 ables (hemoglobin, alkaline phosphatase, and international normalized ratio), together with important

277 oagulopathy (OR: 3.1, 95% CI: 1.7 to 5.8 per international normalized ratio unit), and in those recei

278 nsive care unit stay, but the pretransfusion international normalized ratio value varied widely.

279 care unit admissions, 30% developed abnormal international normalized ratio values (defined as an int

280 ies were minor and short-lived (73% of worst international normalized ratio values 1.6-2.5).

281 ong independent association between abnormal international normalized ratio values and greater intens

282 onist therapy can be complicated by unstable international normalized ratio values and patient-relate

283 Hemoglobin levels and international normalized ratio values were similar in pa

284 to 15% weekly dose changes for out-of-range International Normalized Ratio values.

285 (SD) base deficit was -9.8 (6.3), and median international normalized ratio was 1.3 (interquartile ra

286 The mean international normalized ratio was 1.4 in the warfarin g

287 Median (range) baseline international normalized ratio was 3.90 (1.8-20.0) for t

288 d urea nitrogen, C-Reactive protein, and the international normalized ratio was developed.

289 tients and 40% to nonbleeding patients whose international normalized ratio was normal or only modest

290 after warfarin had been stopped or when the international normalized ratio was subtherapeutic.

291 ion of total treatment time during which the international normalized ratio was within the therapeuti

292 nalysis, recipient's age and elevated pre-LT international normalized ratio were associated with incr

293 tes, albumin, bilirubin, platelet count, and international normalized ratio were independent predicto

294 l thromboplastin time, prothrombin time, and international normalized ratio were reduced from warfari

295 Mean warfarin treatment was 1 year; mean international normalized ratios were 1.9 (IPAH) and 2.0

296 International normalized ratios were monitored using enc

297 However, dosage is, in part, based on international normalized ratio, which is problematic in

298 0044) and took longer to reach a therapeutic international normalized ratio with rivaroxaban versus w

299 ges (P = 0.0002), spent less time with their international normalized ratio within the target range (

300 warfarin at a dose adjusted to maintain the international normalized ratio within the therapeutic ra